CN115040512A - Pharmaceutical composition and preparation method thereof - Google Patents
Pharmaceutical composition and preparation method thereof Download PDFInfo
- Publication number
- CN115040512A CN115040512A CN202210901324.7A CN202210901324A CN115040512A CN 115040512 A CN115040512 A CN 115040512A CN 202210901324 A CN202210901324 A CN 202210901324A CN 115040512 A CN115040512 A CN 115040512A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- sodium picosulfate
- sodium
- bentonite
- citric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition and a preparation method thereof. The preparation method of the pharmaceutical composition comprises the following steps: and step S1: dispersing sodium picosulfate in a solvent to obtain a dispersion liquid; and step S2: mixing the dispersion liquid with bentonite to obtain a mixture; and step S3: mixing the mixture with magnesium oxide and citric acid to obtain a pharmaceutical composition; the mass ratio of the bentonite to the sodium picosulfate is more than 300 and less than or equal to 700, the sodium picosulfate is dispersed in a solvent and then mixed with the bentonite, the sodium picosulfate is completely absorbed and wrapped by utilizing the layered structure of the bentonite and then mixed with the magnesium oxide and the citric acid, the method can well isolate the sodium picosulfate from the sodium citrate, the sodium picosulfate is uniformly dispersed, the thermal stability of the pharmaceutical composition is obviously improved, the content of the sodium picosulfate is obviously improved after the pharmaceutical composition is placed at a high temperature for 10 days, and the content of impurities is obviously reduced.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a pharmaceutical composition and a preparation method thereof.
Background
The compound sodium picosulfate particle is a new drug developed by the drug manufacturing company of huiling, and the trade name is as follows: PREPOPIK TM Petalities for colonoscopy, XPreparation for bowel cleansing prior to radiographic examination. The product is marketed in China in 2018 and 10 months. Specification: each bag contains active ingredients of sodium picosulfate 10mg, magnesium oxide 3.5g, citric acid 12.0g, and auxiliary material of potassium bicarbonate. After the product is dissolved, the magnesium oxide and the citric acid can react to generate the magnesium citrate to play a role in causing diarrhea. Sodium picosulfate is a prodrug that is converted to the active metabolite by bacteria in the colon after oral administration: bis (p-hydroxyphenyl) -pyridyl-2-methane (BHPM) can directly stimulate intestinal mucosa, promote intestinal peristalsis, inhibit water absorption in intestinal tract, and perform catharsis effect. Compared with the traditional intestine clearing agent such as polyethylene glycol, the product has the advantages of small liquid dosage, good effect and high patient compliance.
The product contains sodium picosulfate, magnesium oxide and citric acid as active ingredients, and potassium bicarbonate as an auxiliary material, and the sodium picosulfate content is lower and only accounts for 0.62 percent, and the materials are salts, are easy to dissolve in water, and are difficult to obtain particles with uniform content by using a general preparation technology, so that great challenges are provided for a preparation process. Patent CN101820859 "process for preparing a pharmaceutical product comprising citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical composition comprising fine particles obtained by the process and intermediates" discloses a formulation process: a. applying (in a spraying manner) a sodium picosulfate solution to the surface of the potassium bicarbonate to obtain particles 1; b. mixing magnesium oxide and citric acid, and adhering the magnesium oxide to the surface of the citric acid to obtain particles 2; c. mixing the granules 1 and 2 to obtain granules 3, and subpackaging the granules 3 to obtain the product. However, researches show that the product obtained by the method has poor thermal stability, and the problems of reduction of the content of sodium picosulfate and increase of the content of impurities are easy to occur after the product is placed for a period of time.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to overcome the defect of low thermal stability of the compound sodium picosulfate particles in the prior art, so that the pharmaceutical composition and the preparation method thereof are provided.
The invention provides a preparation method of a pharmaceutical composition containing sodium picosulfate, magnesium oxide and citric acid, which comprises the following steps:
and step S1: dispersing sodium picosulfate in a solvent to obtain a dispersion liquid;
and step S2: mixing the dispersion liquid with bentonite to obtain a mixture;
and step S3: mixing the mixture with magnesium oxide and citric acid to obtain a pharmaceutical composition; the mass ratio of the bentonite to the sodium picosulfate is more than 300 and less than or equal to 700.
Further, the mass ratio of the bentonite to the sodium picosulfate is 500.
Further, the solvent is glycerol.
The dispersion obtained by using glycerin as a solvent can be well absorbed by bentonite to obtain a powdery mixture, and the dispersion can be mixed with the bentonite by a small amount for many times. For example 3-5 times.
Further, in the step S3, the mixture further comprises a step of mixing with carrageenan before mixing with the magnesium oxide and the citric acid.
Further, the mass ratio of the sodium picosulfate to the carrageenan is 0.01:1-3, and preferably 0.01: 2.
Further, the mass ratio of the sodium picosulfate to the magnesium oxide to the citric acid is 0.01:3.5: 12; and/or the mass ratio of the solvent to the bentonite is 1: 5-7.
Further, in the step S3, a step of mixing the mixture with a flavoring agent is further included, preferably, the flavoring agent is saccharin sodium and/or essence.
Furthermore, the pharmaceutical composition contains 0.19 to 0.25 weight percent of saccharin sodium and 0.19 to 0.25 weight percent of essence.
Further, the mass content of the sodium picosulfate in the pharmaceutical composition is 0.039% -0.047%.
The invention also provides a pharmaceutical composition prepared by the preparation method.
The technical scheme of the invention has the following advantages:
1. the preparation method of the pharmaceutical composition provided by the invention comprises the following steps: and S1: dispersing sodium picosulfate in a solvent to obtain a dispersion liquid; and step S2: mixing the dispersion liquid with bentonite to obtain a mixture; and step S3: mixing the mixture with magnesium oxide and citric acid to obtain a pharmaceutical composition, wherein the mass ratio of the bentonite to the sodium picosulfate is more than 300 and less than or equal to 700; the sodium picosulfate is dispersed in the solvent and then mixed with the bentonite, the sodium picosulfate is completely absorbed and wrapped by utilizing the layered structure of the bentonite and then mixed with the magnesium oxide and the citric acid, the method and the control of the mass ratio of the bentonite to the sodium picosulfate can well isolate the sodium picosulfate and the sodium citrate, the sodium picosulfate is uniformly dispersed, the thermal stability of the pharmaceutical composition is obviously improved, and the thermal stability experiment result shows that the reduction degree of the sodium picosulfate content and the improvement degree of the impurity content of the pharmaceutical composition are obviously improved after the pharmaceutical composition is placed at high temperature for 10 days.
In the step S3, the mixture further includes a step of mixing with carrageenan before mixing with the magnesium oxide and the citric acid, and the carrageenan is further wrapped after the bentonite is absorbed, and it is found that the bentonite and the carrageenan are used in combination, so that the pharmaceutical composition has better thermal stability.
2. According to the preparation method of the pharmaceutical composition provided by the invention, researches show that the thermal stability of the pharmaceutical composition can be further improved by controlling the mass ratio of the bentonite to the sodium picosulfate to be 500.
3. According to the preparation method of the pharmaceutical composition provided by the invention, researches show that the thermal stability of the pharmaceutical composition can be further improved by controlling the mass ratio of the sodium picosulfate to the carrageenan to be 0.01:1-3, especially 0.01: 2.
Detailed Description
The following examples are provided to further understand the present invention, not to limit the scope of the present invention, but to provide the best mode, not to limit the content and the protection scope of the present invention, and any product similar or similar to the present invention, which is obtained by combining the present invention with other prior art features, falls within the protection scope of the present invention.
The examples do not show the specific experimental steps or conditions, and can be performed according to the conventional experimental steps described in the literature in the field. The reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially. Wherein the essence is powder orange essence, and is purchased from Huabao peacock food science and technology development limited company in Jiangxi province.
Example 1
The present invention provides a pharmaceutical composition comprising sodium picosulfate, magnesium oxide, and citric acid, formulated as follows:
the preparation method comprises the following steps: dispersing sodium picosulfate in glycerol to obtain a dispersion; evenly mixing the dispersion liquid with bentonite for 3 times to obtain a mixture, wherein the mixture is powdery; adding carrageenan into the mixture, and mixing for 4min at the rotation speed of 12 rpm; then adding magnesium oxide, citric acid, saccharin sodium and essence, and mixing for 5min at the rotation speed of 12 rpm.
Example 2
The present invention provides a pharmaceutical composition comprising sodium picosulfate, magnesium oxide, and citric acid, formulated as follows:
the preparation method comprises the following steps: dispersing sodium picosulfate in glycerol to obtain a dispersion; evenly mixing the dispersion liquid with bentonite for 3 times to obtain a mixture, wherein the mixture is powdery; adding magnesium oxide, citric acid, sodium saccharin and essence into the mixture, and mixing at 12rpm for 5 min.
Example 3
The present invention provides a pharmaceutical composition comprising sodium picosulfate, magnesium oxide, and citric acid, formulated as follows:
the preparation method is the same as that of example 1.
Example 4
The present invention provides a pharmaceutical composition comprising sodium picosulfate, magnesium oxide, and citric acid, formulated as follows:
the preparation method is the same as that of example 1.
Example 5
The present invention provides a pharmaceutical composition comprising sodium picosulfate, magnesium oxide, and citric acid, formulated as follows:
the preparation method is the same as that of example 1.
Comparative example 1
The present comparative example provides a pharmaceutical composition comprising sodium picosulphate, magnesium oxide and citric acid, formulated as follows:
the preparation method comprises the following steps: mixing sodium picosulfate, magnesium oxide, citric acid, saccharin sodium and essence at rotation speed of 12rpm for 5 min.
Comparative example 2
The present comparative example provides a pharmaceutical composition comprising sodium picosulphate, magnesium oxide and citric acid, formulated as follows:
the preparation method comprises the following steps: mixing sodium picosulfate and carrageenan, and mixing for 4min at the rotation speed of 12 rpm; adding magnesium oxide, citric acid, saccharin sodium and essence into the mixture, and mixing at 12rpm for 5 min.
Comparative example 3
The present comparative example provides a pharmaceutical composition comprising sodium picosulphate, magnesium oxide and citric acid, formulated as follows:
the preparation method comprises the following steps: a. dissolving sodium picosulfate in 50mg water to obtain a sodium picosulfate solution, applying the sodium picosulfate solution to the surface of potassium bicarbonate by using a fluidized bed, and drying to obtain particles 1;
b. mixing magnesium oxide and citric acid, and adhering the mixed magnesium oxide to the surface of the citric acid to obtain particles 2;
c. mixing the granules 1 and 2 to obtain granules 3, and subpackaging the granules 3 to obtain the product.
Comparative example 4
The present invention provides a pharmaceutical composition comprising sodium picosulfate, magnesium oxide, and citric acid, formulated as follows:
the preparation method is the same as that of example 1.
Experimental example 1
Thermal stability experiments: the pharmaceutical compositions prepared in the above examples and comparative examples were respectively left at 60 ℃ for 10 days, and the pharmaceutical compositions of each group were measuredThe contents of related substances (impurity A and impurity B) and sodium picosulfate contained before and after placing are specifically as follows: weighing the pharmaceutical compositions of the examples and the comparative examples according to the unit prescription amount, respectively putting the pharmaceutical compositions into 200ml measuring bottles, adding 35ml of 0.063mol/L dipotassium hydrogen phosphate solution (phosphoric acid for adjusting pH to 4.5), shaking for dispersing, carrying out ultrasonic treatment for 5 minutes until the mixture is completely mixed, cooling, adding 35ml of acetonitrile, fully shaking and carrying out ultrasonic treatment for 5 minutes, cooling, diluting with phosphate buffer solution with pH4.5 to scale, shaking up, filtering, and taking the subsequent filtrate as a test solution; taking a proper amount of reference substances of the impurity A (CAS32500-19-9) and the impurity B (CAS603-41-8), accurately weighing, and adding acetonitrile: the mixed solution of phosphate buffer solution (35: 165 by volume) at pH4.5 was dissolved and diluted to a solution containing 0.075. mu.g of impurity A and 0.075. mu.g of impurity B per 1ml, which was used as a control solution. Each of examples and comparative examples used components other than sodium picosulfate and prepared blank samples according to the same process, and the blank samples were weighed and prepared into blank sample solutions according to the test sample solution preparation methods. Performing high performance liquid chromatography (China pharmacopoeia 2020 edition general rule 0512) test by using C 8 A chromatographic column: linear gradient elution was carried out using 0.062mol/L dipotassium hydrogen phosphate solution (phosphoric acid adjusted pH to 4.5) -acetonitrile (86: 14 by volume) as mobile phase a and 0.063mol/L dipotassium hydrogen phosphate solution (phosphoric acid adjusted pH to 4.5) -acetonitrile (40: 60 by volume) as mobile phase B, the gradient elution procedure being as shown in the following table:
flow rate was 1.5ml per minute; the column temperature was 30 ℃ and the detection wavelength was 230 nm. Taking 100 mul of each of a test solution, a reference solution and a blank sample solution, respectively injecting the solutions into a liquid chromatograph, recording a chromatogram, counting chromatographic peaks corresponding to the blank sample, calculating the contents of sodium picosulfate, the impurity A and the impurity B according to an external standard method by using peak areas, wherein the total impurity content (%) is the content of the impurity A plus the content of the impurity B, and the result is shown in the following table:
TABLE 1 results for the substances and sodium picosulfate content (%)
As can be seen from the results shown in the above table, after being left at high temperature for 10 days, compared with comparative examples 1 to 4, the content of sodium picosulfate in the pharmaceutical compositions prepared in examples 1 to 5 of the present invention is significantly increased, the total impurity content is significantly reduced, or the reduction degree of the content of sodium picosulfate and the increase degree of the total impurity content are significantly improved, which indicates that the thermal stability is significantly increased. As is clear from comparison of example 1 with examples 2, 3 and 4, the present invention can further improve the stability of the product by using bentonite in combination with carrageenan or by limiting the mass ratio of sodium picosulfate to carrageenan within a preferred range. As is clear from comparison between example 1 and example 5, the present invention can further improve the stability of the product by limiting the mass ratio of sodium picosulfate to bentonite within a preferred range.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.
Claims (10)
1. A process for the preparation of a pharmaceutical composition comprising sodium picosulphate, magnesium oxide and citric acid comprising the steps of:
and step S1: dispersing sodium picosulfate in a solvent to obtain a dispersion liquid;
and step S2: mixing the dispersion liquid with bentonite to obtain a mixture;
and S3: mixing the mixture with magnesium oxide and citric acid to obtain a pharmaceutical composition; the mass ratio of the bentonite to the sodium picosulfate is more than 300 and less than or equal to 700.
2. The method according to claim 1, wherein the mass ratio of the bentonite to the sodium picosulfate is 500.
3. The production method according to claim 1 or 2, wherein the solvent is glycerin.
4. The method according to any one of claims 1 to 3, wherein the step of S3, the mixture further comprises a step of mixing with carrageenan before mixing with the magnesium oxide and the citric acid.
5. The preparation method according to claim 4, wherein the mass ratio of the sodium picosulfate to the carrageenan is 0.01:1-3, preferably 0.01: 2.
6. The preparation method according to any one of claims 1 to 5, wherein the mass ratio of the sodium picosulfate to the magnesium oxide to the citric acid is 0.01:3.5: 12; and/or the mass ratio of the solvent to the bentonite is 1: 5-7.
7. The method of any one of claims 1-6, wherein step S3 further comprises the step of mixing the mixture with a flavoring agent, preferably saccharin sodium and/or a flavoring.
8. The process according to claim 7, wherein the pharmaceutical composition comprises 0.19 to 0.25 wt% of saccharin sodium and 0.19 to 0.25 wt% of flavoring.
9. The preparation method according to any one of claims 1 to 8, wherein the pharmaceutical composition contains sodium picosulfate in an amount of 0.039% to 0.047% by mass.
10. A pharmaceutical composition made by the process of any one of claims 1-9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210901324.7A CN115040512B (en) | 2022-07-28 | 2022-07-28 | Pharmaceutical composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210901324.7A CN115040512B (en) | 2022-07-28 | 2022-07-28 | Pharmaceutical composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115040512A true CN115040512A (en) | 2022-09-13 |
| CN115040512B CN115040512B (en) | 2023-06-20 |
Family
ID=83166670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210901324.7A Active CN115040512B (en) | 2022-07-28 | 2022-07-28 | Pharmaceutical composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115040512B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259899A1 (en) * | 2003-04-08 | 2004-12-23 | Sanghvi Suketu P. | Combination therapy for constipation |
| CN101406457A (en) * | 2007-10-12 | 2009-04-15 | 辉凌国际制药（瑞士）有限公司 | Process for the manufacture of a pharmaceutical product |
| JP2010083820A (en) * | 2008-09-30 | 2010-04-15 | Kobayashi Pharmaceut Co Ltd | Composition for oral administration |
| CN101820859A (en) * | 2007-10-12 | 2010-09-01 | 辉凌国际制药（瑞士）有限公司 | Preparation comprises the method for the drug products of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, comprises the pharmaceutical composition and the intermediate of the particulate that obtains by this method |
| JP2010235537A (en) * | 2009-03-31 | 2010-10-21 | Kobayashi Pharmaceutical Co Ltd | Oral drug |
| CN102648980A (en) * | 2003-11-19 | 2012-08-29 | 萨利克斯药物公司 | Colonic purgative composition with soluble binding agent |
| WO2016015055A1 (en) * | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
| CN112603927A (en) * | 2020-12-21 | 2021-04-06 | 苏州二叶制药有限公司 | A pharmaceutical composition containing sodium picosulfate, magnesium oxide, citric acid and potassium bicarbonate, and its preparation method |
| CN113648327A (en) * | 2021-08-24 | 2021-11-16 | 山东京卫制药有限公司 | A pharmaceutical composition containing sodium picosulfate, magnesium oxide, citric acid and/or potassium bicarbonate, and its preparation method |
-
2022
- 2022-07-28 CN CN202210901324.7A patent/CN115040512B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040259899A1 (en) * | 2003-04-08 | 2004-12-23 | Sanghvi Suketu P. | Combination therapy for constipation |
| CN102648980A (en) * | 2003-11-19 | 2012-08-29 | 萨利克斯药物公司 | Colonic purgative composition with soluble binding agent |
| CN101406457A (en) * | 2007-10-12 | 2009-04-15 | 辉凌国际制药（瑞士）有限公司 | Process for the manufacture of a pharmaceutical product |
| CN101820859A (en) * | 2007-10-12 | 2010-09-01 | 辉凌国际制药（瑞士）有限公司 | Preparation comprises the method for the drug products of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, comprises the pharmaceutical composition and the intermediate of the particulate that obtains by this method |
| JP2010083820A (en) * | 2008-09-30 | 2010-04-15 | Kobayashi Pharmaceut Co Ltd | Composition for oral administration |
| JP2010235537A (en) * | 2009-03-31 | 2010-10-21 | Kobayashi Pharmaceutical Co Ltd | Oral drug |
| WO2016015055A1 (en) * | 2014-07-25 | 2016-01-28 | Ironwood Pharmaceuticals, Inc. | Colon cleansing compositions |
| CN112603927A (en) * | 2020-12-21 | 2021-04-06 | 苏州二叶制药有限公司 | A pharmaceutical composition containing sodium picosulfate, magnesium oxide, citric acid and potassium bicarbonate, and its preparation method |
| CN113648327A (en) * | 2021-08-24 | 2021-11-16 | 山东京卫制药有限公司 | A pharmaceutical composition containing sodium picosulfate, magnesium oxide, citric acid and/or potassium bicarbonate, and its preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115040512B (en) | 2023-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102138903B (en) | Everolimus solid oral medicinal composition | |
| CN102861106B (en) | Preparation method of compound paracetamol and amantadine pellets | |
| CN112716903B (en) | Amlodipine dry suspension and preparation method thereof | |
| CN114288257B (en) | Fluvoxamine maleate tablet and preparation method thereof | |
| CN112516083B (en) | Ibuprofen suspension and preparation method thereof | |
| CN106798750B (en) | A kind of preparation method of compound omeprazole dry suspension | |
| CN115040512B (en) | Pharmaceutical composition and preparation method thereof | |
| CN104997744B (en) | A kind of high stability capecitabine tablet and preparation method thereof | |
| CN112791054B (en) | Dry granulation method of dry suspension | |
| CN104788421A (en) | Erdosteine compound for treating respiratory tract inflammation and preparation method of erdosteine compound | |
| CN106860404A (en) | A kind of sildenafil citrate taste masking resin complexes and its application | |
| CN109908104B (en) | Amoxicillin capsule and preparation method thereof | |
| CN105693793B (en) | A kind of Ribavirin compound and its pharmaceutical composition | |
| CN114366757A (en) | Compound polyethylene glycol electrolyte and preparation method thereof | |
| CN105796498B (en) | A kind of powder coating folic acid and preparation method thereof | |
| CN110101670B (en) | Aztreonam injection preparation and preparation method thereof | |
| CN108498481B (en) | Cefixime composition and preparation method thereof | |
| CN103315983B (en) | Rasagiline preparation and preparation method thereof | |
| EP4327805A1 (en) | 13c methacetin granule, and preparation method therefor and use thereof | |
| CN115634205B (en) | Acetylcysteine particles and preparation method thereof | |
| CN103239411B (en) | Cefdinir, citric acid and sodium citrate dry suspension composition | |
| CN114533700B (en) | Naproxen oral preparation and preparation method thereof | |
| CN112336711B (en) | Glucozine lysine orally disintegrating tablet | |
| CN105078922A (en) | Medicine sildenafil citrate composition capsule for treating male impotence | |
| CN114748432B (en) | Preparation process of traditional Chinese medicine compound granules |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |